Literature DB >> 29554340

Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011).

Achille Aouba1, Solange Gonzalez Chiappe2, Mireille Eb3, Claire Delmas1, Hubert de Boysson1, Boris Bienvenu1, Grégoire Rey3, Alfred Mahr2,4.   

Abstract

OBJECTIVES: Comprehensive analyses of cause-specific death patterns in GCA are sparse. We studied the patterns and time trends in GCA-related mortality using a large death certificate database.
METHODS: We obtained multiple-cause-of-death data from the French national death certificate database for 1980-2011. GCA-associated deaths were defined as decedents ⩾55 years old with GCA listed as an underlying or non-underlying cause of death. Time trends of death rates were analysed and the mean age at death with GCA and in the general population ⩾55 years old were calculated. Standardized mortality odds ratios (SMORs) were calculated for 17 selected causes of death (based on 2000-11 data).
RESULTS: The analyses pertained to approximately 15 000 death certificates listing GCA (including approximately 6300 for 2000-11). Annual standardized death rates for GCA increased to a peak in 1997 and then decreased (Spearman's correlation test, both P < 0.0001). Mean age at death was higher for GCA than for general population decedents (Student's t-test, P < 0.0001). GCA deaths were frequently or strongly associated with aortic aneurysm and dissection (1.85% of death certificates, SMOR: 3.09, 95% CI: 2.48, 3.82), hypertensive disease (20.78%, SMOR: 2.22, 95% CI: 1.97, 2.50), diabetes mellitus (11.27%, SMOR: 1.96, 95% CI: 1.72, 2.23), certain infectious and parasitic diseases (12.12%, SMOR: 1.76, 95% CI: 1.55, 2.00) and ischaemic heart disease (16.54%, SMOR: 1.45, 95% CI: 1.35, 1.64).
CONCLUSION: GCA is associated with increased risk of dying from large-vessel disease, other cardiovascular diseases and potentially treatment-related co-morbidities. These findings help provide better insights into the outcomes of GCA.

Entities:  

Mesh:

Year:  2018        PMID: 29554340     DOI: 10.1093/rheumatology/key028

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

Review 1.  Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.

Authors:  Alvise Berti; Roberto Caporali; Carlomaurizio Montecucco; Giuseppe Paolazzi; Sara Monti
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 2.  An Updated Review of Cardiovascular Events in Giant Cell Arteritis.

Authors:  Hubert de Boysson; Achille Aouba
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

3.  Patients' Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study.

Authors:  Cyril Dumain; Jonathan Broner; Erik Arnaud; Emmanuel Dewavrin; Jan Holubar; Myriam Fantone; Benoit de Wazières; Simon Parreau; Pierre Fesler; Philippe Guilpain; Camille Roubille; Radjiv Goulabchand
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

4.  Neural network and logistic regression diagnostic prediction models for giant cell arteritis: development and validation.

Authors:  Edsel B Ing; Neil R Miller; Angeline Nguyen; Wanhua Su; Lulu L C D Bursztyn; Meredith Poole; Vinay Kansal; Andrew Toren; Dana Albreki; Jack G Mouhanna; Alla Muladzanov; Mikaël Bernier; Mark Gans; Dongho Lee; Colten Wendel; Claire Sheldon; Marc Shields; Lorne Bellan; Matthew Lee-Wing; Yasaman Mohadjer; Navdeep Nijhawan; Felix Tyndel; Arun N E Sundaram; Martin W Ten Hove; John J Chen; Amadeo R Rodriguez; Angela Hu; Nader Khalidi; Royce Ing; Samuel W K Wong; Nurhan Torun
Journal:  Clin Ophthalmol       Date:  2019-02-21

5.  Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Authors:  L K Brekke; B-T S Fevang; A P Diamantopoulos; J Assmus; E Esperø; C G Gjesdal
Journal:  Arthritis Res Ther       Date:  2019-06-25       Impact factor: 5.156

Review 6.  One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment.

Authors:  Marc Dinkin; Editha Johnson
Journal:  Curr Treat Options Neurol       Date:  2021-01-16       Impact factor: 3.598

7.  Systemic autoimmune disease as a cause of death: mortality burden and comorbidities.

Authors:  Marianna Mitratza; Bart Klijs; A Elisabeth Hak; Jan W P F Kardaun; Anton E Kunst
Journal:  Rheumatology (Oxford)       Date:  2021-03-02       Impact factor: 7.580

Review 8.  Giant Cell Arteritis and Cardiac Comorbidity.

Authors:  Magela Arias; Milad Heydari-Kamjani; Marc M Kesselman
Journal:  Cureus       Date:  2021-02-17

Review 9.  [Diagnostics and treatment of giant cell arteritis].

Authors:  Markus Kraemer; Jana Becker; Thorsten Alexander Bley; Andreas Steinbrecher; Jens Minnerup; Bernhard Hellmich
Journal:  Nervenarzt       Date:  2021-11-03       Impact factor: 1.297

10.  Distribution patterns of arterial affection and the influence of glucocorticoids on 18F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis.

Authors:  Martin Freesmeyer; Alexander Pfeil; Leander Malich; Falk Gühne; Tobias Hoffmann; Ansgar Malich; Tobias Weise; Peter Oelzner; Gunter Wolf
Journal:  RMD Open       Date:  2022-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.